House Bill Would Expand Rx Market, But Negatives Draw PhRMA Protest

Government negotiation of drug prices for the public plan option and Medicaid-level rebates for dual eligibles (individuals qualifying for Medicare and Medicaid) in Part D would be particularly hard for the industry to swallow.